172 related articles for article (PubMed ID: 34855117)
1. Rhythm- or rate-control strategies according to 4S-AF characterization scheme and long-term outcomes in atrial fibrillation patients: the FAMo (Fibrillazione Atriale in Modena) cohort.
Malavasi VL; Vitolo M; Colella J; Montagnolo F; Mantovani M; Proietti M; Potpara TS; Lip GYH; Boriani G
Intern Emerg Med; 2022 Jun; 17(4):1001-1012. PubMed ID: 34855117
[TBL] [Abstract][Full Text] [Related]
2. Characterization of atrial fibrillation in real-world patients: testing the 4S-AF scheme in the Spanish and French cohorts of the EORP-AF Long-Term General Registry.
Rivera-Caravaca JM; Piot O; Roldán-Rabadán I; Denis A; Anguita M; Mansourati J; Pérez-Cabeza A; Marijon E; García-Seara J; Leclercq C; García-Bolao I; Lellouche N; Potpara T; Boriani G; Fauchier L; Lip GYH; Marín F
Europace; 2022 Feb; 24(2):202-210. PubMed ID: 34374759
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility and prognostic implications of the novel 4S-AF scheme to characterize and evaluate patients with atrial fibrillation: a report from ESC-EHRA EORP-AF Long-Term General Registry.
Ding WY; Proietti M; Boriani G; Fauchier L; Blomström-Lundqvist C; Marin F; Potpara TS; Lip GYH;
Europace; 2022 May; 24(5):721-728. PubMed ID: 35446354
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility and prognostic implications of the 4S-AF scheme: Report from Asia Pacific Heart Rhythm Society Atrial Fibrillation Registry.
Chao TF; Tse HF; Teo WS; Park HW; Shimizu W; Chen SA; Lip GYH;
Eur J Clin Invest; 2022 Oct; 52(10):e13825. PubMed ID: 35700114
[TBL] [Abstract][Full Text] [Related]
5. Prognostic implications of the 4S-AF scheme to characterize new-onset atrial fibrillation after myocardial infarction.
Luo J; Li Z; Qin X; Zhang X; Liu X; Zhang W; Xu W; Zhang Y; Fang Y; Liu B; Wei Y;
Eur J Intern Med; 2023 Jul; 113():38-44. PubMed ID: 37037721
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of the 4S-AF scheme in predicting progression of atrial fibrillation: data from the RACE V study.
Artola Arita V; Van De Lande ME; Khalilian Ekrami N; Nguyen BO; Van Melle JM; Geelhoed B; De With RR; Weberndörfer V; Erküner Ö; Hillege H; Linz D; Ten Cate H; Spronk HMH; Koldenhof T; Tieleman RG; Schotten U; Crijns HJGM; Van Gelder IC; Rienstra M
Europace; 2023 Apr; 25(4):1323-1331. PubMed ID: 36857318
[TBL] [Abstract][Full Text] [Related]
7. 4S-AF scheme and ABC pathway guided management improves outcomes in atrial fibrillation patients.
Guo Y; Imberti JF; Kotalczyk A; Wang Y; Lip GYH;
Eur J Clin Invest; 2022 Jun; 52(6):e13751. PubMed ID: 35080269
[TBL] [Abstract][Full Text] [Related]
8. Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating 'valvular heart disease' in a nationwide cohort study.
Lip GYH; Jensen M; Melgaard L; Skjøth F; Nielsen PB; Larsen TB
Europace; 2019 Jan; 21(1):33-40. PubMed ID: 29986001
[TBL] [Abstract][Full Text] [Related]
9. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study.
Bonde AN; Lip GY; Kamper AL; Hansen PR; Lamberts M; Hommel K; Hansen ML; Gislason GH; Torp-Pedersen C; Olesen JB
J Am Coll Cardiol; 2014 Dec; 64(23):2471-82. PubMed ID: 25500231
[TBL] [Abstract][Full Text] [Related]
10. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial.
Packer DL; Mark DB; Robb RA; Monahan KH; Bahnson TD; Poole JE; Noseworthy PA; Rosenberg YD; Jeffries N; Mitchell LB; Flaker GC; Pokushalov E; Romanov A; Bunch TJ; Noelker G; Ardashev A; Revishvili A; Wilber DJ; Cappato R; Kuck KH; Hindricks G; Davies DW; Kowey PR; Naccarelli GV; Reiffel JA; Piccini JP; Silverstein AP; Al-Khalidi HR; Lee KL;
JAMA; 2019 Apr; 321(13):1261-1274. PubMed ID: 30874766
[TBL] [Abstract][Full Text] [Related]
11. Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry.
Lip GY; Laroche C; Popescu MI; Rasmussen LH; Vitali-Serdoz L; Dan GA; Kalarus Z; Crijns HJ; Oliveira MM; Tavazzi L; Maggioni AP; Boriani G
Europace; 2015 Dec; 17(12):1777-86. PubMed ID: 26321406
[TBL] [Abstract][Full Text] [Related]
12. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.
Gallego P; Roldán V; Torregrosa JM; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):312-8. PubMed ID: 22319005
[TBL] [Abstract][Full Text] [Related]
13. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.
O'Brien EC; Simon DN; Thomas LE; Hylek EM; Gersh BJ; Ansell JE; Kowey PR; Mahaffey KW; Chang P; Fonarow GC; Pencina MJ; Piccini JP; Peterson ED
Eur Heart J; 2015 Dec; 36(46):3258-64. PubMed ID: 26424865
[TBL] [Abstract][Full Text] [Related]
14. Impact of renal impairment on atrial fibrillation: ESC-EHRA EORP-AF Long-Term General Registry.
Ding WY; Potpara TS; Blomström-Lundqvist C; Boriani G; Marin F; Fauchier L; Lip GYH;
Eur J Clin Invest; 2022 Jun; 52(6):e13745. PubMed ID: 35000206
[TBL] [Abstract][Full Text] [Related]
15. Characteristics and outcomes of atrial fibrillation patients with or without specific symptoms: results from the PREFER in AF registry.
Bakhai A; Darius H; De Caterina R; Smart A; Le Heuzey JY; Schilling RJ; Zamorano JL; Shah M; Bramlage P; Kirchhof P
Eur Heart J Qual Care Clin Outcomes; 2016 Oct; 2(4):299-305. PubMed ID: 29474715
[TBL] [Abstract][Full Text] [Related]
16. Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry.
Proietti M; Laroche C; Drozd M; Vijgen J; Cozma DC; Drozdz J; Maggioni AP; Boriani G; Lip GY;
Am Heart J; 2016 Nov; 181():83-91. PubMed ID: 27823697
[TBL] [Abstract][Full Text] [Related]
17. Use of statins and adverse outcomes in patients with atrial fibrillation: An analysis from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) general registry pilot phase.
Proietti M; Laroche C; Nyvad O; Haberka M; Vassilikos VP; Maggioni AP; Boriani G; Lip GYH;
Int J Cardiol; 2017 Dec; 248():166-172. PubMed ID: 28859841
[TBL] [Abstract][Full Text] [Related]
18. Adherence to the 4S-AF Scheme in the Balkan region: Insights from the BALKAN-AF survey.
Kozieł-Siołkowska M; Mihajlovic M; Nedeljkovic M; Pavlovic N; Paparisto V; Music L; Trendafilova E; Dan AR; Kusljugic Z; Dan GA; Lip GY; Potpara TS
Kardiol Pol; 2022; 80(4):461-467. PubMed ID: 35176169
[TBL] [Abstract][Full Text] [Related]
19. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).
Lip GYH; Collet JP; Caterina R; Fauchier L; Lane DA; Larsen TB; Marin F; Morais J; Narasimhan C; Olshansky B; Pierard L; Potpara T; Sarrafzadegan N; Sliwa K; Varela G; Vilahur G; Weiss T; Boriani G; Rocca B;
Europace; 2017 Nov; 19(11):1757-1758. PubMed ID: 29096024
[TBL] [Abstract][Full Text] [Related]
20. Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.
Pokorney SD; Holmes DN; Thomas L; Fonarow GC; Kowey PR; Reiffel JA; Singer DE; Freeman JV; Gersh BJ; Mahaffey KW; Hylek EM; Naccarelli GV; Ezekowitz MD; Piccini JP; Peterson ED;
JAMA Cardiol; 2019 Aug; 4(8):756-764. PubMed ID: 31268487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
